top of page
Founded in 2010, CG Oncology is a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies to combat cancer. Their lead proprietary agent, CG0070, is a cancer selective oncolytic virus that can be used alone or combined with other immune checkpoint inhibitors to fight cancer cells. CG0070 has completed the phase 2, single arm, open label, multicenter study (BOND2) and has been shown to be a safe agent in BCG-failure non-muscle invasive bladder cancer (NMIBC).
bottom of page